ATE262517T1 - Thiopyranderivate as mmp-inhibitoren - Google Patents

Thiopyranderivate as mmp-inhibitoren

Info

Publication number
ATE262517T1
ATE262517T1 AT00900122T AT00900122T ATE262517T1 AT E262517 T1 ATE262517 T1 AT E262517T1 AT 00900122 T AT00900122 T AT 00900122T AT 00900122 T AT00900122 T AT 00900122T AT E262517 T1 ATE262517 T1 AT E262517T1
Authority
AT
Austria
Prior art keywords
thiopyrane
derivatives
mmp inhibitors
mmp
inhibitors
Prior art date
Application number
AT00900122T
Other languages
English (en)
Inventor
Kiyoshi Taniguchi
Masahiro Neya
Takeshi Terasawa
Hitoshi Yamazaki
Kentaro Sato
Kumi Hosoi
Yasuyo Tomishima
Noriko Yoshida
Yoshimasa Imamura
Hisashi Takasugi
Hiroyuki Setoi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP8068A external-priority patent/AUPP806899A0/en
Priority claimed from AUPQ1702A external-priority patent/AUPQ170299A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE262517T1 publication Critical patent/ATE262517T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT00900122T 1999-01-07 2000-01-06 Thiopyranderivate as mmp-inhibitoren ATE262517T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP8068A AUPP806899A0 (en) 1999-01-07 1999-01-07 Cyclic compound
AUPQ1702A AUPQ170299A0 (en) 1999-07-19 1999-07-19 Cyclic compound
PCT/JP2000/000018 WO2000040576A2 (en) 1999-01-07 2000-01-06 Thiopyran compounds as inhibitors of mmp

Publications (1)

Publication Number Publication Date
ATE262517T1 true ATE262517T1 (de) 2004-04-15

Family

ID=25645967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00900122T ATE262517T1 (de) 1999-01-07 2000-01-06 Thiopyranderivate as mmp-inhibitoren

Country Status (16)

Country Link
EP (1) EP1140895B1 (de)
JP (1) JP2002534424A (de)
KR (1) KR20010102968A (de)
CN (1) CN1343206A (de)
AR (1) AR022213A1 (de)
AT (1) ATE262517T1 (de)
BR (1) BR0008589A (de)
CA (1) CA2357874A1 (de)
DE (1) DE60009260T2 (de)
ES (1) ES2213563T3 (de)
HK (1) HK1045312A1 (de)
HU (1) HUP0104859A3 (de)
MX (1) MXPA01006896A (de)
RU (1) RU2221792C2 (de)
TR (1) TR200101936T2 (de)
WO (1) WO2000040576A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR755501A0 (en) * 2001-09-07 2001-09-27 Fujisawa Pharmaceutical Co., Ltd. Cyclic compound
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
WO2003031431A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
BRPI0810719A8 (pt) 2007-04-30 2016-03-08 Abbott Lab Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
FR2962649B1 (fr) * 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
RU2536205C2 (ru) * 2012-09-27 2014-12-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Нефтехимии И Катализа Ран Способ получения 5-метоксикарбонил-1,3-дитиана, обладающего фунгицидной активностью
WO2015028960A1 (en) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801300D0 (en) * 1988-01-21 1988-02-17 May & Baker Ltd New compositions of matter
SU1643544A1 (ru) * 1989-02-07 1991-04-23 Институт Химии Нефти И Природных Солей Ан Казсср Алкиловые эфиры гетероциклических оксибутадииновых кислот в качестве мономеров дл получени полимеров, использующихс дл защиты от коррозии
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors

Also Published As

Publication number Publication date
WO2000040576A3 (en) 2001-03-22
HK1045312A1 (zh) 2002-11-22
TR200101936T2 (tr) 2001-12-21
ES2213563T3 (es) 2004-09-01
EP1140895A2 (de) 2001-10-10
HUP0104859A2 (en) 2002-10-28
MXPA01006896A (es) 2002-06-04
HUP0104859A3 (en) 2002-11-28
DE60009260D1 (de) 2004-04-29
BR0008589A (pt) 2002-01-29
EP1140895B1 (de) 2004-03-24
CN1343206A (zh) 2002-04-03
CA2357874A1 (en) 2000-07-13
DE60009260T2 (de) 2004-08-05
KR20010102968A (ko) 2001-11-17
AR022213A1 (es) 2002-09-04
RU2221792C2 (ru) 2004-01-20
WO2000040576A2 (en) 2000-07-13
JP2002534424A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
PT1181017E (pt) Inibidores de metaloproteases
IS2116B (is) 4-fenyl-pyridin afleiður
DE50010060D1 (de) Thiazolylamid-derivate
ATE263748T1 (de) Admantan-derivate
PT1194404E (pt) Inibidores de aspartil-protease
ATE524441T1 (de) Vla-4-inhibitoren
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
ATE257148T1 (de) Propargyletherderivate
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
ATE293592T1 (de) Resorcinderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties